Advances in oncolytic virotherapy

Recent years have seen rapid advances in the preclinical development and clinical evaluation of oncolytic (cancer-lysing) virus-based therapies, and these are emerging as treatment modality for some cancers. There are challenges to address, however, if we are to maximize the impact of these therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Stephen J., Bell, John C., Engeland, Christine E., McFadden, Grant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053215/
https://www.ncbi.nlm.nih.gov/pubmed/35603308
http://dx.doi.org/10.1038/s43856-022-00098-4
_version_ 1784696950303490048
author Russell, Stephen J.
Bell, John C.
Engeland, Christine E.
McFadden, Grant
author_facet Russell, Stephen J.
Bell, John C.
Engeland, Christine E.
McFadden, Grant
author_sort Russell, Stephen J.
collection PubMed
description Recent years have seen rapid advances in the preclinical development and clinical evaluation of oncolytic (cancer-lysing) virus-based therapies, and these are emerging as treatment modality for some cancers. There are challenges to address, however, if we are to maximize the impact of these therapies in patients.
format Online
Article
Text
id pubmed-9053215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90532152022-05-20 Advances in oncolytic virotherapy Russell, Stephen J. Bell, John C. Engeland, Christine E. McFadden, Grant Commun Med (Lond) Viewpoint Recent years have seen rapid advances in the preclinical development and clinical evaluation of oncolytic (cancer-lysing) virus-based therapies, and these are emerging as treatment modality for some cancers. There are challenges to address, however, if we are to maximize the impact of these therapies in patients. Nature Publishing Group UK 2022-04-07 /pmc/articles/PMC9053215/ /pubmed/35603308 http://dx.doi.org/10.1038/s43856-022-00098-4 Text en © Springer Nature Limited 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Viewpoint
Russell, Stephen J.
Bell, John C.
Engeland, Christine E.
McFadden, Grant
Advances in oncolytic virotherapy
title Advances in oncolytic virotherapy
title_full Advances in oncolytic virotherapy
title_fullStr Advances in oncolytic virotherapy
title_full_unstemmed Advances in oncolytic virotherapy
title_short Advances in oncolytic virotherapy
title_sort advances in oncolytic virotherapy
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053215/
https://www.ncbi.nlm.nih.gov/pubmed/35603308
http://dx.doi.org/10.1038/s43856-022-00098-4
work_keys_str_mv AT russellstephenj advancesinoncolyticvirotherapy
AT belljohnc advancesinoncolyticvirotherapy
AT engelandchristinee advancesinoncolyticvirotherapy
AT mcfaddengrant advancesinoncolyticvirotherapy

Ejemplares similares